Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cue Biopharma, Inc.NASDAQ: CUE

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $5.69M rose 1250.6% year over year, ahead of the +308.6% change in trailing-twelve-month gross profit. Sequentially, it fell 74.1% from the prior quarter. Over 3 fiscal years it compounded at +180.5% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1250.6% holds above the trailing-twelve-month pace of +308.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.69M-74.1% QoQ
Last fiscal yearDec 2025
$27.47M+195.7% YoY
LTMMar 2026
$32.65M+308.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1250.6%——
1 year+195.7%——
3-year CAGR+180.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
27.47M USD
Year-over-year change
+195.7%
4-year CAGR
+13.2%

Gross Profit vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 gross profit of $32.65M is the highest of the 7 companies compared; the peer median is -$39.5K.
  • Its year-over-year change of +308.6% is the 3rd highest of 7, against a peer median of -100.1%.
  • Gross profit amounts to 99.8% of revenue for CUE, versus a peer median of 87.2%.
CUE Competitors Peer median
Gross Profit for CUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +6860.8%—87.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%——
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding CUE) -$39.5K-100.1%+164.4%87.2%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.94M1.25M5.49M9.29M27.47M
Cost of Revenue(1.78M)038.1M00
Gross Profit16.72M1.25M(32.61M)9.29M27.47M
Gross Margin111.9%100.0%-593.9%100.0%100.0%
Research & Development41.35M38.58M40.8M36.3M37.74M
Selling, General & Admin17.31M16.17M16.68M14.59M16.24M
Operating Expenses60.43M54.47M19.54M50.79M53.99M
Depreciation & Amortization(1.78M)1.81M3.44M2.35M3.48M
EBITDA(45.44M)(50.49M)(46.05M)(37.53M)(22.27M)
EBITDA Margin-304.1%-4055.5%-838.8%-404.1%-81.1%
Operating Income(43.71M)(53.23M)(52.15M)(41.5M)(26.52M)
Operating Margin-292.6%-4275.1%-949.9%-446.9%-96.6%
Interest Income45.9K928.24K2.66M1.62M807K
Interest Expense0713.82K1.25M796K357K
Other Income / Expenses45.9K215K1.42M826K419K
Income Before Tax(43.67M)(53.01M)(50.73M)(40.67M)(26.1M)
Pre-Tax Margin-292.3%-4257.8%-924.1%-438.0%-95.0%
Income Tax Expense495K000500K
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Net Margin-295.6%-4257.8%-924.1%-438.0%-96.9%
EPS (Basic)(42.30)(44.70)(33.30)(21.60)(8.40)
EPS (Diluted)(42.30)(44.70)(33.30)(21.60)(8.40)
Weighted Avg Shares1.04M1.19M1.53M1.88M3.16M
Weighted Avg Shares (Diluted)1.04M1.19M1.53M1.88M3.16M

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.